Biodel Announces Data Presentation at the 51st Annual

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Biodel Announces Data Presentation at the 51st Annual Meeting of the EASD

DANBURY, CT --(Marketwired - September 14, 2015) - Biodel Inc. ( NASDAQ : BIOD ) announces an abstract describing a clinical standardized meal challenge study performed with BIOD-531, an ultra-rapid acting/basal insulin formulation, was selected for oral presentation at the 51 st Annual Meeting of the European Association for the Study of Diabetes (EASD) being held in Stockholm, Sweden from September 14 - 18, 2015.

Dr. Linda Morrow, M.D. (Profil Institute for Clinical Research, Chula Vista, CA) will present BIOD-531 demonstrates superior prandial glucose control, post-meal dosing flexibility, and less insulin "stacking" compared to marketed prandial/basal insulins on Tuesday, September 15, 2015, in the Oral Session entitled OP 01 Insulin analogues: Is newer always better? scheduled for 10:45 AM - 12:15 PM CET (4:45 - 6:15 AM EDT).

Dr. Alan Krasner, Biodel's Chief Medical Officer, stated: "The results of this study performed in patients with type 1 or type 2 diabetes and severe insulin resistance are consistent with those seen in a previous standard meal challenge study performed in patients with type 2 diabetes and more moderate degrees of insulin resistance. In these studies, the unique biphasic profile of BIOD-531 has been shown to translate into improved postprandial control compared to marketed prandial/basal insulins in a wide spectrum of patients who use moderate to high doses of insulin."

The presentation abstracts can be accessed by members through the association's website, www.EASD.org .

About Biodel Inc.

Biodel Inc. is a specialty biopharmaceutical company focused on the development and commercialization of innovative treatments for diabetes that may be safer, more effective and more convenient for patients. Biodel's product candidates are developed by applying proprietary technologies to existing drugs in order to improve their therapeutic profiles. More information about Biodel is available at www.biodel.com .

Safe-Harbor Statement

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include statements about future activities related to the clinical development plans for the company's drug candidates, including the potential timing, design and outcomes of clinical trials; and the company's ability to develop and commercialize product candidates. Forward-looking statements represent our management's judgment regarding future events. All statements, other than statements of historical facts, including statements regarding our strategy, future operations, future clinical trial results, future financial position, future revenues, projected costs, prospects, plans and objectives of management are forward-looking statements. The words "anticipates," "believes," "could," "estimates," "expects," "intends," "may," "plans," "potential," "predicts," "projects," "should," "will," "would" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. The company's forward-looking statements are subject to a number of known and unknown risks and uncertainties that could cause actual results, performance or achievements to differ materially from those described or implied in the forward-looking statements, including, but not limited to, the success of our product candidates, particularly our proprietary formulations of injectable insulin that are designed to be absorbed more rapidly than the "rapid-acting" mealtime insulin analogs presently used to treat patients with type 1 and type 2 diabetes and our glucagon presentation that is intended to treat patients experiencing severe hypoglycemia; our ability to conduct pivotal clinical trials, other tests or analyses required by the U.S. Food and Drug Administration, or FDA, to secure approval to commercialize a proprietary formulation of injectable insulin or a stable glucagon presentation; the success of our formulation development work with insulin analog-based formulations of a proprietary injectable insulin and a stable glucagon presentation; our ability to secure approval from the FDA for our product candidates under Section 505(b)(2) of the Federal Food, Drug, and Cosmetic Act; the progress, timing or success of our research, development and clinical programs, including any resulting data analyses; our ability to develop and commercialize a proprietary formulation of injectable insulin that may be associated with less injection site discomfort than Linjeta™ (formerly referred to as VIAject ® ), which is the subject of a complete response letter we received from the FDA; our ability to enter into collaboration arrangements for the commercialization of our product candidates and the success or failure of any such collaborations into which we enter, or our ability to commercialize our product candidates ourselves; our ability to protect our intellectual property and operate our business without infringing upon the intellectual property rights of others; the degree of clinical utility of our product candidates; the ability of our major suppliers to produce our products in our final dosage form; our commercialization, marketing and manufacturing capabilities and strategies; our ability to accurately estimate anticipated operating losses, future revenues, capital requirements and our needs for additional financing; and other factors identified in our most recent report on Form 10-Q for the quarter ended December 31, 2014. The company disclaims any obligation to update any forward-looking statements as a result of events occurring after the date of this press release.

BIOD-G

CONTACT: Clayton Robertson +1 (646) 378 2964

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Teamsters Ratify Contract, Averting Waste Strike

Updated Category News Views 117

Big Win for Teamsters Local 350 You ever seen a strike averted by sheer willpower and unity? That’s what's happened here with the workers at South San Francisco Scavenger Company. These folks—drivers, mechanics, sorters, and utility workers—all banded together under the Teamsters Local 350 and showed management what's what by securing a contract they deserve. We're...

Continue Reading
Duolingo Faces Class Action: Key Investor Steps

Updated Category News Views 162

Navigating Turbulent Times with Duolingo Holy moly, the dumpster fire that is the Duolingo (NASDAQ:DUOL) legal saga just got hotter. If you snagged yourself some shares between May 2, 2025, and February 26, 2026, you'd better sit down and grab some antacids—because the nauseating roller coaster is far from over. Robbins LLP is rounding up the troops for a class action,...

Continue Reading
Apani Adds Kelsun Assets to Its Natural Fiber Platform

Updated Category News Views 29

A materials deal with more chemistry than chest-thumping Seaweed and cotton have landed under one roof, which is a lot more interesting than another apparel brand slapping a green label on ordinary fabric. Apani said November 17 it acquired the assets of Keel Labs, bringing Keel's seaweed-based Kelsun fiber alongside Apani's enhanced cotton-cellulose filament technology....

Continue Reading
PawnMate Boosts Inventory Efficiency for Pawnshops

Updated Category News Views 213

RFID Technology: Breathing New Life into Pawnshops Let's get things rolling with the cold, hard truth that pawnshops aren't exactly what most folks expect when it comes to cutting-edge technology. But times are a-changin', and PawnMate’s RFID Inventory Module is the latest twist in this industry storyline. It's like swapping out a rusty toolbox for a brand-new set of...

Continue Reading
Philadelphia Firm Targets 100 Toys for Children This Holiday

Updated Category News Views 90

A hundred unopened toys can look modest on paper, yet that is exactly why this Philadelphia effort lands differently than the usual chest-thumping corporate charity chatter. van der Veen, Hartshorn & Levin has set a clear holiday target: collect 100 new, unwrapped toys for children in the Philadelphia area through the U.S. Marine Corps Reserve Toys for Tots program. No...

Continue Reading
CSMI Boosts CT's Cybersecurity for Defense Sector

Updated Category News Views 132

Paving the Way for Cybersecurity Excellence Out in chilly Connecticut, CSMI made a mark. The State's Office of Manufacturing picked them to join the advisory council for the Defense CyberSecure Program (CT-DCP). It ain’t just a pat on the back; it's a big deal for the region's defense and aerospace manufacturing gang. Connecticut's got its eyes set on beefing up its...

Continue Reading
Greenberg Traurig Cheers Clients' 69th GRAMMY® Nods

Updated Category News Views 101

A Momentous Occasion for Greenberg Traurig's Entertainment Clients Oh, the glamour and glitz of the music world! There's nothing quite like the GRAMMY® Awards to stir up a blend of excitement, ego, and anxiety in the industry. This time around, the lawyers over at Greenberg Traurig are beaming with pride as their clients scoop up nominations for the 69th Annual GRAMMY®...

Continue Reading
AR Cards in Casino Gaming: A High-Stakes Revolution

Updated Category News Views 138

A New Breed of Casino Experience Walk into a casino today, and you might just enter a whole new reality. No, this isn’t a cheesy magician’s trick or a glitzy PR stunt—this is the real deal brought to you by augmented reality (AR) trading cards. Imagine the slots you love wrapped in a sci-fi movie where characters leap out, tap you on the shoulder, and call you by...

Continue Reading
Wall Street Gains Hold Amid Volatility Drop

Updated Category News Views 66

A Week of Gains and Regulatory Moves Right out of the gate, it’s been a decent stretch for Wall Street. Weekly gains kept the party going, even as traders navigated the usual hurdles. Stocks finished the week with a solid performance—all the heavy hitters like Dow, S&P 500, Nasdaq, and Russell 2000 ended on a high note, waltzing uphill past where many imagined...

Continue Reading
Lennar Faces Securities Fraud Lawsuit: Investor Insights

Updated Category News Views 208

Investors in Lennar: Navigating the Legal Storm Hold onto your hats, folks. Lennar Corporation (NYSE: LEN) is up against it with a brand-spanking-new securities fraud lawsuit helmed by Schall, Brown & Schwartz LLP (SBS). This isn't just a couple of investors grumbling over cocktails; it’s a full-blown class action that’s waving the legal banner under the Securities...

Continue Reading

Top 5 Most Recently Viewed Articles

Alliance Entertainment Expands Leadership with Robert Oram

Updated Category News Views 137

Alliance Entertainment Welcomes Robert Oram as EVP Alliance Entertainment Holding Corporation (NASDAQ: AENT) has made a significant addition to its leadership team with the appointment of Robert Oram as the Executive Vice President. This strategic move, announced recently, aims to bolster the company's efforts in expanding its home entertainment division. Oram, a veteran...

Continue Reading
Teradyne Inc: Navigating AI Growth in Semiconductor Testing

Updated Category News Views 155

Teradyne Inc (NASDAQ: TER) was one of those stocks that had traders buzzing back in 2023 when it saw gains up to 50% early in the year. That kind of momentum, especially outpacing the Philadelphia Semiconductor Index, had folks dreaming big. But reality hit later on as the market pulled back, reminding everyone that nothing lasts forever in this volatile game. Market...

Continue Reading
Transforming Landscapers' Cash Flow with Duranta's Payments

Updated Category News Views 163

Duranta Unveils a Game-Changer for Landscapers' Payments Duranta, the AI-driven platform for landscaping professionals, is set to reshape how landscaping businesses handle payments. Recently, they introduced an innovative feature that embeds secure payment links directly into customer invoices. This new function streamlines transaction methods for landscapers, making it...

Continue Reading
Analyzing Market Trends: The Case of WR Berkley Stock

Updated Category News Views 146

Understanding WR Berkley and Its Market Position WR Berkley Corporation (NYSE: WRB) has been making headlines recently due to its fluctuating short interest levels. The company, known for its diverse insurance offerings, recorded a significant rise in its short percent of float, now standing at 22.48%. This figure comes from its recent announcement that approximately 7.96...

Continue Reading
Timbercreek Financial to Host Q4 Results Call - Key Details Inside

Updated Category News Views 153

Timbercreek Financial's Upcoming Conference Call Timbercreek Financial (TSX: TF) is gearing up for an important conference call to discuss its financial results for the last quarter. This call is set for 1:00 p.m. (ET) on a Wednesday. The insights into the company’s performance will be revealed shortly after the markets close. Stakeholders and interested parties are...

Continue Reading